FEATURED NEWS

• HDA Statement on Proposed DEA Regulations

  October 28, 2019

  In response to the Drug Enforcement Administration’s (DEA) proposed regulations related to the review and monitoring of annual production quotas, the Healthcare Distribution Alliance (HDA) released the following statement.

• Drew and Mauch Reelected to Lead HDA Board of Directors

  October 21, 2019

  The Healthcare Distribution Alliance (HDA) announced that Greg Drew, RPh, President of Value Drug Company, and Robert Mauch, PhD, PharmD, EVP and Group President of AmerisourceBergen Corporation, were recently elected to second terms as Chairman and Vice Chairman of the HDA Board of Directors.

• HDA Statement on the Ensuring Patient Access and Effective Drug Enforcement Act

  September 13, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement regarding media reporting on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

• HDA Statement on HHS-FDA "Safe Importation Action Plan"

  July 31, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement on the release of the “Safe Importation Action Plan” by the Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA).

• New Analysis Notes the Critical and Evolving Role Pharmaceutical Distributors Play in U.S. Healthcare

  July 30, 2019

  A new report published by the Healthcare Distribution Alliance (HDA) and Deloitte Consulting LLP highlights the value distributors provide to the United States healthcare ecosystem and estimates pharmaceutical distributors generate between $33 and $53 billion in cost savings annually. The Role of Distributors in the US Health Care Industry provides insights into the importance of wholesalers in driving efficiency and innovation across the pharmaceutical supply chain — both today and over the next several years.